The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J01 | Antibacterials for systemic use | |
3 | J01D | Other beta-lactam antibacterials | |
4 | J01DI | Other cephalosporins |
Code | Title | |
---|---|---|
J01DI01 | Ceftobiprole medocaril | |
J01DI02 | ||
J01DI03 | ||
J01DI04 | ||
J01DI54 |
Active Ingredient | Description | |
---|---|---|
Cefiderocol |
Cefiderocol is a siderophore cephalosporin. In addition to passive diffusion through outer membrane porin channels, cefiderocol is able to bind to extracellular free iron via its siderophore side chain, allowing active transport into the periplasmic space of Gram-negative bacteria through siderophore uptake systems. Cefiderocol subsequently binds to penicillin binding proteins (PBPs), inhibiting bacterial peptidoglycan cell wall synthesis which leads to cell lysis and death. |
|
Ceftaroline fosamil |
In vitro studies have shown that ceftaroline is bactericidal and able to inhibit bacterial cell wall synthesis in methicillin-resistant Staphylococcus aureus (MRSA) and penicillin non-susceptible Streptococcus pneumoniae (PNSP) due to its affinity for the altered penicillin-binding proteins (PBPs) found in these organisms. As a result, minimum inhibitory concentrations (MICs) of ceftaroline against a proportion of these organisms tested fall into the susceptible range. |
|
Ceftobiprole medocaril |
Ceftobiprole exerts bactericidal activity through binding to important penicillin-binding proteins (PBPs) in susceptible species. |
|
Faropenem |
Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. Like other beta-lactam antibiotics, faropenem acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis. |
Title | Information Source | Document Type | |
---|---|---|---|
FETCROJA Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
FETROJA Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
ZEVTERA Powder for concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ZINFORO Powder for concentrate for solution | European Medicines Agency (EU) | MPI, EU: SmPC |